US › Healthcare

Neumora Therapeutics, Inc. (NMRA)

US · Healthcare · Biotechnology

$1.60-2.44%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-53.5M
Profit YoY
+21.4%
EPS
$-0.30
EPS estimate
$-0.31

EPS came in at -0.30 against a street estimate of -0.31 — a beat of 3.2%.

Key statistics

Market cap
$298.3M
Forward P/E
0.0
P/B
4.21
Book value
$0.39
EPS (TTM)
$-1.33
52-week high
$3.65
52-week low
$0.83
50-day MA
$1.65
200-day MA
$2.18
Beta
2.77

Analyst view

Analysts rate Neumora Therapeutics, Inc. a buy (3 buy, 5 hold, 0 sell out of 8) with an average price target of $6.28.

Shareholding

Insiders
23.60%
Institutions
57.89%

Largest institutional holders

FundStake
Siren, L.L.C.4.65%
SoftBank Group Corp3.33%
Perceptive Advisors LLC2.79%
MIC Capital Management UK LLP2.44%
Vanguard Capital Management, LLC2.13%
FMR Inc1.92%
Wellcome Trust Ltd1.81%
Millennium Management LLC1.51%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Neumora Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.